Amylyx Pharmaceuticals Inc (AMLX)vsZoetis Inc (ZTS)
AMLX
Amylyx Pharmaceuticals Inc
$13.83
+1.24%
HEALTHCARE · Cap: $1.53B
ZTS
Zoetis Inc
$116.71
+0.67%
HEALTHCARE · Cap: $51.09B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates -1423709% more annual revenue ($9.47B vs $-665,000). ZTS leads profitability with a 28.2% profit margin vs 0.0%. ZTS earns a higher WallStSmart Score of 64/100 (C+).
AMLX
Avoid31
out of 100
Grade: F
ZTS
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AMLX.
Margin of Safety
-29.1%
Fair Value
$99.69
Current Price
$116.71
$17.02 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Every $100 of equity generates 66 in profit
Strong operational efficiency at 34.7%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Expensive relative to growth rate
Trading at 14.9x book value
3.0% revenue growth
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : AMLX
AMLX has a balanced fundamental profile.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.2% and operating margin at 34.7%.
Bear Case : AMLX
The primary concerns for AMLX are EPS Growth, Market Cap, Profit Margin.
Bear Case : ZTS
The primary concerns for ZTS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.85 is elevated, increasing financial risk.
Key Dynamics to Monitor
ZTS carries more volatility with a beta of 0.95 — expect wider price swings.
ZTS is growing revenue faster at 3.0% — sustainability is the question.
ZTS generates stronger free cash flow (732M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ZTS scores higher overall (64/100 vs 31/100), backed by strong 28.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amylyx Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amylyx Pharmaceuticals Inc (AMLX) is a biopharmaceutical innovator focused on developing groundbreaking therapies for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). Its flagship candidate, AMX0035, utilizes a unique mechanism to offer neuroprotection and improve patient quality of life, marking a significant advancement in ALS treatment. Supported by a robust clinical pipeline and a thorough understanding of neurological disease complexities, Amylyx is well-positioned to meet critical unmet medical needs and enhance therapeutic options for ALS and related disorders.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?